Patients With Primary Biliary Cholangitis(PBC)

Primary Biliary Cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by the progressive destruction of small intrahepatic bile ducts, leading to chronic cholestasis, hepatic fibrosis, and, in advanced stages, cirrhosis. Recent advances in the understanding of PBC pathophysiology have highlighted the central role of immune, inflammatory, and metabolic alterations in disease onset and progression.

Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of PBC (biochemical criteria, antibody positivity and/or histological examination) * The patient is a candidate for first- or second-line PPAR agonist therapy, as clinical practice, for the treatment of PBC * The patient requires comprehensive metabolic monitoring, as per clinical practice * Signed the informed consent form Exclusion Criteria: * Patients with a prior diagnosis of diabetes mellitus currently on insulin therapy * Patients on treatment known to significantly affect glycemic values (e.g., GLP-1 receptor agonists, SGLT2 inhibitors, systemic corticosteroids) * Patients with a life expectancy or estimated time to liver transplantation of less than 6 months